Basis for Inclusion: Altria Group donated to the Trump White House Ballroom renovation, contributed $1 million to the Trump-Vance Inaugural Committee, and donated $1 million to the pro-Trump super PAC MAGA Inc. During the Trump administration, Altria received significant regulatory benefits including the withdrawal of a proposed menthol cigarette ban, the abandonment of a nicotine-reduction rule, and a new FDA enforcement discretion policy allowing the sale of unauthorized e-cigarettes and nicotine pouches. Altria executives attended a May 2026 meeting with President Trump at his golf club that preceded these regulatory changes. This profile documents the factual relationship between political donations and government actions affecting the donor. Inclusion is based on Anchor D (Financial transactions creating conflicts of interest in public office).

Overview

Altria Group, Inc. (NYSE: MO), headquartered in Richmond, Virginia, is one of the largest tobacco companies in the world. Its subsidiaries include Philip Morris USA (manufacturer of Marlboro, the top-selling cigarette brand in the United States), John Middleton (cigars), U.S. Smokeless Tobacco Company, and NJOY (e-cigarettes). Altria reported net revenues of approximately $20.7 billion in 2024. The company has a significant financial interest in FDA regulation of tobacco, nicotine, and e-cigarette products.

Altria has been identified as a donor to the Trump White House Ballroom renovation project, a $400 million privately funded construction project that replaced the demolished East Wing of the White House. The company also contributed $1 million to the 2025 Trump-Vance Inaugural Committee and $1 million to MAGA Inc., the principal pro-Trump super PAC. These donations occurred during a period in which the Trump administration took a series of regulatory actions favorable to the tobacco industry, including withdrawing the proposed menthol cigarette ban, abandoning the nicotine-reduction rule, and issuing new FDA guidance allowing the marketing of unauthorized e-cigarettes.

Six U.S. senators — Dick Durbin, Elizabeth Warren, Edward Markey, Jeff Merkley, Richard Blumenthal, and Jack Reed — wrote a public letter to Altria on June 4, 2026, stating the company had enjoyed a “lucrative payday” after spending millions on political donations and lobbying. The senators requested details on all donations, meetings with administration officials, and products that would benefit from the regulatory changes. [CREDIBLY REPORTED]

Political Spending and Access

White House Ballroom Donation

Altria Group was listed among approximately 40 donors to the Trump White House Ballroom project, a $400 million privately funded renovation managed through the Trust for the National Mall. The specific donation amount has not been publicly disclosed; the ballroom funding agreement — obtained by Public Citizen through a FOIA lawsuit — permits donors to remain anonymous and excludes White House officials from conflict-of-interest reviews. [DOCUMENTED — Public Citizen FOIA lawsuit, Washington Post reporting]

Public Citizen’s “Ballroom Billions” report found that two-thirds of the 27 identified corporate donors have recent government contracts totaling $338 billion over the past five and a half years. The report noted Altria’s federal contract data as “N/A” — indicating the company’s primary benefit from the administration comes through regulatory relief rather than direct federal contracts. [DOCUMENTED — Public Citizen report, 2026]

Trump Inaugural Donation

Altria Group contributed $1 million to the Trump-Vance Inaugural Committee in late 2024. The contribution was disclosed in congressional lobbying records and reported by NOTUS, Rolling Stone, and other outlets. A few days after Trump took office on January 20, 2025, the administration formally withdrew the proposed menthol cigarette ban. [DOCUMENTED — FEC filings; NOTUS, Rolling Stone reporting]

MAGA Inc. Super PAC Donation

Altria Client Services, Altria’s subsidiary, donated $1 million to MAGA Inc., the pro-Trump super PAC, on May 9, 2025. This donation was disclosed in FEC Schedule A filings. [DOCUMENTED — FEC filing, MAGA Inc. Schedule A]

Altria PAC Contributions

Altria Group’s political action committee (AltriaPAC) distributed $821,000 to federal candidates in the 2023–2024 cycle: approximately 69% to Republicans and 30% to Democrats. The PAC contributes to members of both parties who serve on committees with jurisdiction over tobacco regulation. [DOCUMENTED — OpenSecrets, FEC filings]

Direct Access: May 2026 Golf Club Meeting

On or around May 2, 2026, two Altria executives attended a lunch with President Trump at his golf club in Jupiter, Florida. Also present were a senior Reynolds American executive and two Reynolds lobbyists. During the meeting, tobacco executives expressed dissatisfaction with FDA regulation of the industry. President Trump interrupted the conversation to phone FDA Commissioner Marty Makary; when Makary did not answer, Trump called Health Secretary Robert F. Kennedy Jr. and CMS head Dr. Mehmet Oz to complain about the FDA’s regulation of e-cigarettes. [CREDIBLY REPORTED — New York Times, May 2026; SF Examiner; The Daily Beast]

Within approximately one week of this meeting, the FDA issued new enforcement discretion guidance allowing major tobacco companies to sell flavored e-cigarettes and nicotine pouches without premarket authorization.

Government Contracts and Business

Public Citizen’s “Ballroom Billions” report listed Altria Group’s FY 2021–FY 2026 federal contract total as “N/A,” indicating no significant direct federal procurement contracts were identified. Altria’s primary financial relationship with the federal government is regulatory rather than contractual — the company’s revenues are substantially affected by FDA regulation of tobacco products, marketing restrictions, and enforcement priorities. [DOCUMENTED — Public Citizen, 2026]

Regulatory and Enforcement Actions

The Trump administration took a series of regulatory actions between January 2025 and May 2026 that directly benefited Altria Group and the tobacco industry.

Menthol Cigarette Ban Withdrawn (January 21, 2025)

On Trump’s second day in office, the administration formally withdrew the proposed FDA rule that would have banned menthol cigarettes and flavored cigars. This rule had been more than a decade in development across multiple administrations. The FDA proposed the ban in 2022; the Biden administration delayed it indefinitely ahead of the 2024 election. Public health groups estimated the ban could have prevented hundreds of thousands of deaths, particularly among Black smokers who disproportionately use menthol products. Menthol cigarettes — including Altria brands — represent approximately 37% of the U.S. cigarette market. [DOCUMENTED — FDA regulatory filing withdrawal, January 21, 2025; The Hill; Campaign for Tobacco-Free Kids]

Nicotine-Reduction Rule Stalled

The Biden administration issued a proposed FDA rule on January 15, 2025 — five days before leaving office — that would have reduced nicotine in cigarettes to non-addictive levels (from approximately 17.2 mg/g to 0.7 mg/g). While the Trump administration has not formally withdrawn this rule as of June 2026, experts assess it is unlikely to be finalized under the current administration given industry opposition and the administration’s pattern of favorable regulatory treatment. The rule’s public comment period expired September 15, 2025, with no further action taken. [DOCUMENTED — Federal Register, 90 FR 3394, January 16, 2025; FDLI analysis, August 2025]

FDA Enforcement Discretion for E-Cigarettes and Nicotine Pouches (May 2026)

On approximately May 8–10, 2026, the FDA issued new guidance establishing an “enforcement discretion” policy allowing manufacturers to sell e-cigarettes and nicotine pouches without premarket authorization, provided their marketing applications meet certain standards. This guidance:

• Reversed the FDA’s longstanding position that “the pendency of an application does not create a legal safe harbor”
• Was issued without public comment or formal rulemaking
• Could allow 100–200 products to immediately enter the market, with up to 1,000 more potentially eligible
• Bypassed the scientific review process the FDA had maintained for years
• Was issued days before FDA Commissioner Marty Makary resigned on May 12, 2026

Health Secretary Robert F. Kennedy Jr. directed FDA and HHS staff to make the change after Trump’s phone call from the golf club meeting. Rich Danker, RFK Jr.’s top spokesman, resigned in protest over the new vaping policy, writing in his resignation letter that “Senior HHS officials in the immediate office of the secretary have in recent months sought U.S. Food and Drug Administration marketing approval of cigarette flavors that would appeal to children and expose them to nicotine addiction, lung damage and higher risk of cancer.” [CREDIBLY REPORTED — Washington Post; The Hill; Post and Courier; Regulatory Oversight]

FDA Commissioner Resignation

Dr. Marty Makary resigned as FDA Commissioner on May 12, 2026, following the vaping policy changes. One source told CBS News that Makary was “leaving over the e-cigarette dispute” and “didn’t want to approve the flavored varieties but had been forced to by other members of the administration.” Trump had reportedly already signed off on a plan to fire Makary. Kyle Diamantas, an attorney with reported personal ties to Donald Trump Jr., was named acting FDA commissioner. [CREDIBLY REPORTED — CBS News; CNBC; NBC News; Drug Discovery Trends]

Lobbying Activity

Altria Group is among the largest lobbying spenders in the tobacco industry. Lobbying is conducted through its subsidiary Altria Client Services.

Altria self-reports filing more than 400 lobbying reports annually at the state level in addition to federal filings. Key lobbying issues include FDA oversight of tobacco and nicotine products, authorization of smoke-free products, and enforcement against illicit vape markets. [DOCUMENTED — OpenSecrets; Altria Government Affairs disclosure page; Lobbying Disclosure Act filings]

Revolving Door Connections

Altria Group employs a significant number of lobbyists with prior government experience:

In one documented case, Wanyoike Kang’ethe left the Office of Science at the FDA’s Center for Tobacco Products to join Altria’s regulatory affairs department as a top scientist. The Revolving Door Project flagged this move as concerning given Altria’s history of employing scientists to influence tobacco regulation. [CREDIBLY REPORTED — Revolving Door Project; OpenSecrets revolving door data]

The Trump administration rescinded the Biden-era ethics pledge that had restricted former lobbyists from holding senior positions in the agencies they had lobbied. The Campaign Legal Center identified at least 47 former lobbyists serving as senior political appointees in the Trump administration as of April 2026, more than 15 of whom would have been restricted under prior administrations’ ethics pledges. [DOCUMENTED — Campaign Legal Center, April 2026]

Conflict of Interest Analysis

The documented timeline of Altria Group’s political spending and the regulatory actions that followed presents a factual pattern:

1. Late 2024: Altria donated $1 million to the Trump-Vance Inaugural Committee.
2. January 21, 2025: On Trump’s second day in office, the administration withdrew the proposed menthol cigarette ban — a rule that would have significantly affected Altria’s product portfolio.
3. May 9, 2025: Altria Client Services donated $1 million to MAGA Inc.
4. 2025: Altria donated to the White House Ballroom project (amount undisclosed).
5. May 2, 2026 (approx.): Altria executives attended a private lunch with President Trump at his Jupiter golf club, during which Trump called the FDA commissioner and other health officials to complain about tobacco regulation.
6. May 8–10, 2026: The FDA issued enforcement discretion guidance allowing sale of unauthorized e-cigarettes and nicotine pouches, bypassing the normal rulemaking process.
7. May 12, 2026: FDA Commissioner Makary resigned, reportedly because he opposed the policy changes but was overridden.
8. June 4, 2026: Six U.S. senators wrote to Altria describing the regulatory changes as “money well spent” and requesting disclosure of all donations, meetings, and benefiting products.